<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100630</url>
  </required_header>
  <id_info>
    <org_study_id>CN001-023</org_study_id>
    <secondary_id>WP40225</secondary_id>
    <nct_id>NCT03100630</nct_id>
  </id_info>
  <brief_title>Compare Bioavailability of RO7239361 After Subcutaneous Injection</brief_title>
  <official_title>An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RO7239361 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected
      into the arm, thigh, or the stomach. Collect data on safety of RO7239361.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Actual">October 17, 2017</completion_date>
  <primary_completion_date type="Actual">October 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to time of last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events ( AEs)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram findings</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical examination findings</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical laboratory test findings</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: RO7239361</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RO7239361 subcutaneous injections on specified days; abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: RO7239361</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RO7239361 subcutaneous injections on specified days; arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: RO7239361</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RO7239361 subcutaneous injections on specified days; thigh</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7239361</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Treatment A: RO7239361</arm_group_label>
    <arm_group_label>Treatment B: RO7239361</arm_group_label>
    <arm_group_label>Treatment C: RO7239361</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participant as determined by no significant deviations in normal medical and
             surgical history and assessments

          -  Body Mass Index 18 kg/m2 to 32 kg/m2

          -  females must be of non-childbearing potential

        Exclusion Criteria:

          -  tattoos or other skin findings on any of the potential injection sites

          -  history of chronic muscle pain within 30 days prior to study treatment

          -  prior history of IgG1 therapy

        Other protocol defined inclusion and exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

